Fig. 4
From: ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression
ADPGK promotes PCa growth and liver metastasis in vivo. a Tumor-bearing mice in two groups (the tumor of one mouse in the control group did not arise). b Tumor size of the two groups (one mouse in the ADPGK OE group grew 2 subcutaneous tumors, contributing to the final 6 tumors shown in the ADPGK OE group). c Changes in tumor growth size over time. d Cyclin D1 and ADPGK protein expression in xenograft tissues assessed by Western blotting (n = 3). e Verification of tumor tissues from the xenograft mice by immunofluorescence with an ADPGK antibody (n = 3). Scale bar = 50 μm. f Metastatic foci of the liver in the tumor-bearing mice by hematoxylin and eosin (HE) staining (circled in red line). Scale bar = 50 μm. Data are presented as the mean ± SD. **P < 0.01, ****P < 0.0001. PCa prostate cancer, ADPGK ADP-dependent glucokinase, SD standard deviation, NC negative control, OE overexpression